lifestyle.forkstofeet.com

Author: Aptevo Therapeutics

Aptevo Provides State of the Business Report and 2025 Financial Results

March 26, 2026
Aptevo to Participate in March 2026 Conferences

March 19, 2026
Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50%

March 10, 2026
Aptevo Announces Executive Leadership Transitions to Support Next Phase of Growth

February 3, 2026
Aptevo Therapeutics Secures $60 Million Equity Line of Credit to Support Multispecific Portfolio Advancement, Increase Strategic Optionality

January 9, 2026
Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split

December 26, 2025
Aptevo Therapeutics Highlights Compelling Safety and Strong Remission Rates for Mipletamig in Frontline AML at ASH 2025

December 9, 2025